Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 12,238 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Blepharitis
Interventions: Fluticasone Propionate, Placebo; Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Progressive Multiple Sclerosis
Interventions: Obecabtagene autoleucel (obe-cel); Biological
Lead sponsor: Autolus Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Multiple Myeloma
Interventions: Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 30
States / cities: Anchorage, Alaska • Gilbert, Arizona • Berkeley, California + 25 more

Conditions: Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
Interventions: CA102N, LONSURF; Drug
Lead sponsor: Holy Stone Healthcare Co., Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Gilbert, Arizona • Aurora, Colorado • Houston, Texas

Conditions: Kidney Diseases, Kidney Injury, Kidney Failure
Interventions: MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR); Drug · Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more

Conditions: NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions: Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more

Conditions: Multiple Myeloma, Plasmacytoma
Interventions: magnetic resonance imaging, positron emission tomography; Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 26
States / cities: Mobile, Alabama • Little Rock, Arkansas • Salina, Kansas + 11 more

Conditions: Multiple Sclerosis
Interventions: BIIB033, Placebo, Avonex; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more

Conditions: Obesity, Genetic Disorder, Mental Retardation, Developmental Delay
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 99 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions: fezolinetant - reference formulation, Placebo; Drug
Lead sponsor: Shehzad Basaria, M.D.; Other
Eligibility: 40 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Allergic Conjunctivitis
Interventions: Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 5 Years and older
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 7
States / cities: Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more

Conditions: Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interferon alfa, sargramostim, tyrosinase peptide; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 32
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Decatur, Georgia + 24 more

Conditions: Retinitis Pigmentosa Syndromic, Congenital Deafness, Usher Syndrome, Retinitis Pigmentosa and Deafness, Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 2 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 2
States / cities: Bethesda, Maryland • New York, New York

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions: Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Hemophilia a
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: cyclosporine ophthalmic emulsion, placebo; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more

Conditions: Multiple Sclerosis
Interventions: Kemstro; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Timeline: 2005
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Total body irradiation, Mycophenolate Mofetil, Tacrolimus 60, Tacrolimus 90, Tacrolimus 120, Bone marrow transplant; Drug · Radiation · Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: Feraheme, Gadolinium-based contrast; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Stanford, California

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Multiple Myeloma, Diffuse Large B-cell Lymphoma
Interventions: MEDI7247; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more

Conditions: Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
Interventions: GRN1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more

Search by objective public record fields.

Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Brain-Derived Neurotrophic Factor in Obesity and Brain Function

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Natural History and Genetic Studies of Usher Syndrome

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Ocrelizumab Effects on the Metabolome in MS

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)